Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19121892 | 0.98 | HRH3 (0.37) | KDM4EHRH3L3MBTL1SHBGALDH1A1 | |
| SCHEMBL13080712 | 0.94 | L3MBTL1 (0.38) | KDM4EHRH3L3MBTL1 | |
| SCHEMBL24738799 | 0.94 | L3MBTL1 (0.38) | KDM4EHRH3L3MBTL1 | |
| SCHEMBL14701485 | 0.94 | L3MBTL1 (0.38) | KDM4EHRH3L3MBTL1 | |
| SCHEMBL28493502 | 0.82 | KDM4E (0.37) | KDM4EHRH3ALDH1A1GAAHPGD | |
| SCHEMBL10850022 | 0.82 | KDM4E (0.37) | KDM4EHRH3ALDH1A1GAAHPGD | |
| SCHEMBL14431600 | 0.81 | KDM4E (0.39) | KDM4EHRH3SHBGALDH1A1GAA | |
| SCHEMBL13823008 | 0.80 | KDM4E (0.36) | KDM4EHRH3SHBGALDH1A1 | |
| SCHEMBL7177471 | 0.79 | KDM4E (0.38) | KDM4EHRH3SHBGALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL7187634 | 0.78 | HRH3 (0.41) | KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021064077-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS IRAK4 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-08 | — | — | WO | disclosed |
| WO-2015134790-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20100105914-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-7612064-B2 | Sulfopyrroles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
| US-7381827-B2 | 5-Ethoxy-4-(1-(benzyloxycarbonyl)-2-pyrrolidinylcarbonylamino)-5H-furan-2-one; purification by chromatography, selectively crystallization, or dynamic crystallization; useful for preparing caspase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | KDM4E 2337/4885HRH3 445/4885L3MBTL1 2091/4885 |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TYMS, TYMP, HPRT1 | KDM4E 2746/4885HRH3 1540/4885L3MBTL1 690/4885 |
| US-20100105914-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | KDM4E 1279/4885HRH3 4473/4885L3MBTL1 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.